ArticleFrontiers in medicine2025

Efficacy and safety of the third-generation tyrosine kinase inhibitor Olverembatinib in relapsed and persistent minimal residual disease positive Philadelphia chromosome-positive acute lymphoblastic leukemia patients.

Xinwen Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.